RVMD CFO Retains Large Stake After Minor Stock Sale for Tax Purposes

Rhea-AI Filing Summary

Revolution Medicines (RVMD) Chief Financial Officer Jack Anders reported a significant insider transaction on June 16, 2025. The CFO disposed of 2,170 shares at a weighted average price of $39.83 per share, executed through multiple trades ranging from $39.59 to $39.83.

The sale was conducted under a pre-established Rule 10b5-1 trading plan from May 31, 2023, specifically to cover tax withholding obligations related to vesting restricted stock units (RSUs). Following the transaction, Anders maintains beneficial ownership of 113,314 shares, which includes:

• 478 shares acquired through the Employee Stock Purchase Plan on May 31, 2025
• 54,213 restricted stock units (RSUs)

This transaction appears to be a routine tax-related sale rather than a discretionary divestment, suggesting no significant change in the executive's long-term position in the company.

Insider Trade Summary

Net Seller: 2,170 shares

Net Sell 1 txn

Insider Anders Jack

Role Chief Financial Officer

Sold 2,170 shs ($86K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,170	$39.83	$86K

Holdings After Transaction: Common Stock — 113,314 shares (Direct)

Footnotes (4)

1. F1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023.
2. F2. This transaction was executed in multiple trades in prices ranging from $39.5913 to $39.8291, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
3. F3. Includes 478 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2025.
4. F4. Includes 54,213 RSUs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 06/18/2025 - 04:05 PM Learn about SEC filing dates

FAQ

How many shares of RVMD stock did CFO Jack Anders sell on June 16, 2025?

CFO Jack Anders sold 2,170 shares of RVMD common stock on June 16, 2025 at a weighted average price of $39.83 per share.

What was the purpose of RVMD CFO's stock sale in June 2025?

The stock sale was made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023, specifically to satisfy the CFO's tax withholding obligation upon the vesting of restricted stock units (RSUs) after July 15, 2023.

How many RVMD shares does CFO Jack Anders own after the June 2025 transaction?

Following the transaction, Jack Anders beneficially owns 113,314 shares, which includes 478 shares acquired under the Employee Stock Purchase Plan on May 31, 2025 and 54,213 RSUs.

What was the price range of RVMD shares sold by the CFO in the June 2025 transaction?

The shares were sold in multiple trades at prices ranging from $39.5913 to $39.8291 per share, with a weighted average sale price of $39.83.

When did RVMD's CFO establish the 10b5-1 trading plan under which this sale occurred?

The Rule 10b5-1 instruction letter was adopted on May 31, 2023, approximately one year before the reported transaction.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Anders Jack

(Last) (First) (Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/16/2025		S(1)		2,170	D	$39.83(2)	113,314(3)(4)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023.

2. This transaction was executed in multiple trades in prices ranging from $39.5913 to $39.8291, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

3. Includes 478 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2025.

4. Includes 54,213 RSUs.

	/s/ Jack Anders	06/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.